SCTX
Scribe Therapeutics Inc.
SCTX
Scribe Therapeutics Inc.
One IPO priced this past week, joined by four SPACs. Two sizable IPOs and one direct listing are currently scheduled in the week ahead, although some smaller deals may also join the calendar throughou
ALAMEDA, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR tech
Scribe Therapeutics is a Phase 1 clinical-stage biopharma developing in vivo CRISPR gene editing for disease prevention, targeting atherosclerotic cardiovascular disease. SCTX's lead candidate, STX-11